EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cara Therapeutics's enterprise value is $-56.40 Mil.
Cara Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $20.97 Mil. Therefore, Cara Therapeutics's EV-to-Revenue for today is -2.69.
The historical rank and industry rank for Cara Therapeutics's EV-to-Revenue or its related term are showing as below:
CARA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -3.05 Med: 30.26 Max: 5047.14
Current: -2.69
During the past 13 years, the highest EV-to-Revenue of Cara Therapeutics was 5047.14. The lowest was -3.05. And the median was 30.26.
CARA's EV-to-Revenue is ranked better than 94.58% of 1033
companies
in the Biotechnology industry
Industry Median: 7.66
vs CARA: -2.69
The historical data trend for Cara Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cara Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Cara Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cara Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cara Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cara Therapeutics's EV-to-Revenue falls into.
Cara Therapeutics's current Enterprise Value is $-56.40 Mil.
Cara Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics (NAS:CARA) EV-to-Revenue Explanation
Cara Therapeutics's share price for today is $0.6843.
Cara Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.39.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cara Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cara Therapeutics (Cara Therapeutics) Business Description
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CARA has been successfully added to your 